THANK YOU FOR SUBSCRIBING
Since its inception in 2006 by Professor George Kollias—Biomedcode has provided pre-clinical drug evaluation services to more than 114 pharmaceutical and biotech companies worldwide successfully supporting the development of a large number of biosimilars, novel biologics, small molecule inhibitors and novel technological platforms. Pre-clinical data generated from the firm’s successful contract research projects are incorporated in IND applications for FDA, SFDA and EMEA approval. Starting its journey with preclinical models of arthritis supporting the development of multiple human therapeutics targeting TNF—Biomedcode has built a strong reputation, gaining the trust and respect of renowned clients from pharmaceutical companies worldwide.![]()
We are enabling pharmaceutical and biotech companies across the globe to prime their drugs for success by providing ready-made or custom-tailored high-quality pre-clinical services
Share this Article:
Tweet
|
Company
Biomedcode
Headquarters
Athens, Greece
Management
Maria C Denis, PH.D CEO and Niki Karagianni, PH.D, CSO
Description
Biomedcode is a highly innovative Contract Research Organization (CRO) offering a diverse array of advanced pre-clinical evaluation platforms based on a unique collection of spontaneous and induced mouse disease models humanized for TNF, TNFR1, RANKL, IL17A and IL23p19 closely recapitulating the complexity of human inflammatory diseases including arthritis, spondyloarthritis, osteoporosis, psoriasis, multiple sclerosis and others. The company maintains a highly active R&D programme aiming to generate and standardise novel humanised disease models to be used as pre-clinical evaluation platforms as well as tools for the study of disease mechanisms